MedTrace Logo

Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety

NCT05915949 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2023-08-14

No results posted yet for this study

Summary

Diabetes is the most frequently occurring chronic disease along with obesity, hypertension, and hyperlipidemia. The number of patients with diabetes is increasing worldwide. Despite rapid progress in management of diabetes, the problem is that glycemic target goal is still low showing 30-40%. Thus, diabetes has become a serious social, economic, and public health problem beyond individual health problems due to its increasing prevalence.

Conditions

  • Diabetes Type 2

Interventions

DRUG

Dapagliflozin 10mg Tab

Forxiga 10mg Tab once daily will be given to participants for 24 weeks.

DRUG

Lobeglitazone 0.5 mg

Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.

DRUG

Dapagliflozin + Lobeglitazone

Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-10-30
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05915949 on ClinicalTrials.gov